SCHEMBL14855243

SCHEMBL14855243

Cc1ccc(COc2ccc(N)cc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 6/20 0.48
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
CSNK2A1 P68400 2/20 0.43
CYP3A4 P08684 2/20 0.43
AGXT P21549 2/20 0.43
GLA P06280 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14854665 0.87 MRGPRX4 (0.48) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL14854821 0.87 MRGPRX4 (0.55) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL13929749 0.86 MRGPRX4 (0.58) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL14854921 0.84 NPC1 (0.51) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL14855309 0.84 CCR5 (0.52) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3320471 0.84 MAOB (0.56) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL31193398 0.84 MAOB (0.56) MRGPRX4NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL11091418 0.83 FFAR4 (0.48) MRGPRX4NPC1RAB9ACYP3A4AGXT
SCHEMBL632895 0.83 MRGPRX4 (0.57) MRGPRX4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL12173115 0.83 MRGPRX4 (0.58) MRGPRX4NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-9676724-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
CN-102321076-B Preparation method of lapatinib intermediate and analogues thereof USTC UNIV SCIENCE TECH CN 2013-08-21 CN disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
CN-102321076-A The preparation method of lapatinibditosylate midbody and analogue thereof USTC UNIV SCIENCE TECH CN 2012-01-18 CN disclosed
WO-2011153942-A1 CYANOQUINOLINE DERIVATIVES 天津和美生物技术有限公司 (CN) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246443-B2 Cyanoquinoline derivatives CBR3, CYP3A4, CDK1 MRGPRX4 1090/4885NPC1 672/4885RAB9A 2829/4885
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 MRGPRX4 1090/4885NPC1 672/4885RAB9A 2829/4885
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 MRGPRX4 1090/4885NPC1 672/4885RAB9A 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.